Optimizing Bronchopulmonary Cancer Screening
Optimizing the Implementation of Bronchopulmonary Cancer Screening in the Ile de France Region (OPTI-DEPIST-MUT)
Institut Curie
500 participants
Jan 17, 2025
INTERVENTIONAL
Conditions
Summary
The aim of this study is to evaluate the feasibility of performing a first screening for bronchopulmonary cancer by thoracic scanner in a French cohort within a dedicated, effective and structured network in the pilot centers participating in the study.
Eligibility
Inclusion Criteria8
- Participant aged 50 to 74.
- Resident in the Île-de-France region.
- Active smoker or quit smoker for 10 years or less:
- more than 10 cigarettes a day for more than 30 years,
- more than 15 cigarettes a day for more than 25 years.
- The participant has been informed and has signed the consent form.
- Social Security System affiliation.
- Willingness to participate in a smoking cessation program, if currently smoking.
Exclusion Criteria8
- Active cancer or a history of cancer in remission for less than 5 years (except basal cell carcinoma of th skin or epithelioma in situ of the uterine cervix).
- Presence of symptoms suggestive of bronchopulmonary cancer. Participants with these symptoms require immediate diagnostic investigations and are therefore not eligible for screening.
- Weight >= 140 kg.
- Severe comorbidity contraindicating therapeutic options or invasive thoracic diagnostic investigations.
- Inability to climb two flights of stairs without stopping.
- A thoracic CTscan performed within the previous year.
- Persons deprived of liberty or under guardianship.
- Impossibility to undergo the medical monitoring of the trial for geographical, social or psychological reasons.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A first step to identify and recruit people eligible for screening,
A second step for inclusion of participants, with an online self-questionnaire and information, and an inclusion visit to the health center,
A third step with an initial CTscan, with dual interpretation and appropriate management of participants, including follow-up care.
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06439901